PT  - JOURNAL ARTICLE
AU  - Keswani, Amit N.
AU  - Williams, Cody
AU  - Fuloria, Jyotsna
AU  - Polin, Nichole M.
AU  - Jahangir, Eiman
TI  - Rituximab-Induced Acute ST Elevation Myocardial Infarction
DP  - 2015 Jun 20
TA  - Ochsner Journal
PG  - 187--190
VI  - 15
IP  - 2
4099  - http://www.ochsnerjournal.org/content/15/2/187.short
4100  - http://www.ochsnerjournal.org/content/15/2/187.full
SO  - Ochsner J2015 Jun 20; 15
AB  - Background Rituximab has rarely been associated with acute coronary syndrome (ACS). We report the case of a patient in whom rituximab, a monoclonal antibody used to treat lymphomas of B-cell origin, induced ST elevation myocardial infarction.Case Report A 46-year-old male patient diagnosed with stage II non-Hodgkin lymphoma presented to the emergency department with acute crushing, substernal chest pain that radiated to his back 1 day after a chemotherapy infusion with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone. An electrocardiogram revealed normal sinus rhythm with ST elevations in the inferior leads. The patient underwent primary percutaneous coronary intervention (PCI) of his right coronary artery and first diagonal artery with placement of drug-eluting stents. He did well postprocedure and resumed therapy with rituximab under close monitoring by the cardiology and oncology departments without any further cardiac events.Conclusion In patients with ACS because of chemotherapy, complete revascularization during PCI should be considered.